共 75 条
[1]
Smolen JS(2016)Treat-to-target as an approach in inflammatory arthritis Curr Opin Rheumatol 28 297-302
[2]
van Tuyl LH(2010)Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review Arthritis Care Res (Hoboken) 62 108-117
[3]
Felson DT(2017)Baricitinib versus placebo or adalimumab in rheumatoid arthritis N Engl J Med 376 652-662
[4]
Wells G(2015)Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate Ann Rheum Dis 74 333-340
[5]
Taylor PC(2022)Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance Mod Rheumatol 33 647-656
[6]
Keystone EC(2017)Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study Ann Rheum Dis 76 88-95
[7]
van der Heijde D(2019)Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial J Clin Med 8 831-343
[8]
Keystone EC(2022)Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy RMD Open 8 e001994-4960
[9]
Takagi M(2022)Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database Ann Rheum Dis 81 335-369
[10]
Atsumi T(2022)A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19 Adv Ther 39 4910-3962